Dynamic quotes: Off
|
Company Description (as filed with the SEC)
ZIOPHARM Oncology, Inc. is a biopharmaceutical company that seeks to develop and commercialize a diverse portfolio of cancer drugs that can address unmet medical needs through the licensing and development of proprietary small molecule drug candidates and a synthetic biology platform. Our small molecule drug candidates are related to cancer therapeutics already on the market or in development and that can be administered by intravenous, or IV, and/or oral dosing. Our small molecule clinical programs include palifosfamide (ZIO-201), indibulin (ZIO-301) and darinaparsin (ZIO-101). We are also pursuing the development of our synthetic biology platform in the field of cancer pursuant to a partnering arrangement with Intrexon Corporation, or Intrexon. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-1.3 |
| Quarterly EPS Est: | -0.25 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
3.33 |
Data is provided by Zacks Investment Research
